Nancy Pelosi Bought Tempus AI (TEM stock): Best Medical AI Stock?

Coin Crunch
8 followers
3 Video Views·Jan 26, 2025
Over the weekend Nancy Pelosi filed that she bought 50 in the money call options on Tempus AI (TEM stock). In this video I explore what they do, and why Representative Pelosi might think there's hundred's of percentage upside from here.
It's a big weekend for the financial enrichment of the US political class. You have President
Donald Trump announcing his meme coin that has a market value of billions of dollars, that's TRUMP.
His wife also got in on the action, that's Melania. She had her own coin and then
caused the price of Trump to fall. But it's not just President Trump.
You can actually see the excitement, perhaps the grift, on both sides of the aisle with
Honorable Nancy Pelosi disclosing after Friday's market close that she's been very busy in the
buying call options in Alphabet, Amazon, selling Apple stock, buying and selling
NVIDIA. But what really got the market's attention was the announcement that they
purchased 50 call options on Tempest AI stock. TEM is the ticker. This was a purchase of between
50 and $100,000. This was a leveraged purchase because it's using the call options and it's
well in the money for Tempest. So this does make me wonder and make a lot of investors wonder
what's going on because this alone got the animal spirits going for Tempest, causing the stock to
jump 30 to 40 percent. In this video, I'm going to walk you through what are the fundamentals
of Tempest. And my goal with this channel is to try to find potential multibaggers,
the types of stocks that can go hundreds or even thousands percent higher in the years ahead.
And I'd argue Tempest does have the fundamentals that could see that type of multibagger return
over time. And that's what gets me interested. This does not, you know, have just sort of the,
hey, there's a meme product and maybe it's worth zero tomorrow. This does have something that might
be quite special. And so let's walk through what they're building that could suggest they're
building a lot of value over time. Why does Nancy Pelosi, you know, potentially see value in it?
And where do I think about the share price from here? As always, you're watching Unrivaled
Investing. If you enjoy educational investment content, I do appreciate you hitting that thumbs
up. Hit that subscribe button. So looking at Tempest, let's explore TM is the ticker. So they
announced that they're building the leading AI enabled diagnostic platform in the world. OK,
so what does that even mean? So really, what jumps out to me is that they're potentially
building an unrivaled data collection. They have connections with over twenty five hundred
institutions leading to the collection of real time, clinical, molecular and imaging data for
millions of cancer patients. This is quite interesting when you're looking at this.
You know, it does make me wonder, are they building some sort of moat, some sort of competitive
advantage, something that can make them unrivaled, give them the right to win? I've done a previous
YouTube video just exploring, you know, what are moats? Because Warren Buffett talked about
if you have a moat, it sort of gives you the right to win. It's something special that makes
it harder for competitors to disrupt your business. And I'd argue this slide suggests
that they are building some sort of moat. Maybe it's intangible assets. Maybe it's a network
effect because they are connecting to more than 65 percent of all academic medical centers and
more than 50 percent of oncologists in the US. And as a result, they're getting a lot of data,
eight point five million clinical records, one point two million imaging records,
hundreds of thousands of DNA and RNA profiles. This is very relevant data. As you start having
it flow through AI to give you interesting inputs, you know, that could lead to better
treatments. Now, when you look at Tempus AI's business model, it comes down to diagnostic
testings or the genomics segment, licensing and analytical tools. That's their data segment.
And then their application segment. So you have these three segments. These first two are the
vast majority of their revenue. That's genomics and data, the value of genomics. And this is,
you know, smart investors have been talking about this for quite some time.
It really comes down to testing, testing, testing, testing, where the goal is to test patients,
you know, having these diagnostic tests, these assays where you're trying to track,
does this person have cancer? Does this person does this person have the genes that makes them
predisposed to having cancer if they have cancer and they're being treated? How is it going? What's
the cancer signatures suggest if you've already had the treatment and had a favorable response?
OK, are you in some sort of monitoring stage where you're making sure it doesn't flare up again,
doesn't start spreading again? So the tracking, the monitoring, the diagnostic
segment of this market, this is just critical because as prudent investors have talked about
squeezing, I'm thinking about Andy Kessler in particular. He wrote a whole book about this
where he talked about squeezing, you know, improving the costs in terms of the health
care system. Really, it may not come. It's possible, but it may not come from, let's say,
radical new treatments of, let's say, stage four cancer. Really, you can squeeze a lot of the cost
by having much better testing and prevention, catching it at, let's say, stage one or before
versus doing a late stage, you know, sort of intervention where there's a lot more complexity,
uncertainty, and also there's a lot higher probability that the patient doesn't survive.
So this is why it's so important to say, OK, let's have preventative catching, you know,
early stage detection. This is just so important. And as you look at the genomics business model,
you can see their number of tests has just grown amazingly over the last few years, from 40,000
to over 200,000 from 2019 to 2023. So growing 50 percent a year. 2024, it's growing closer to 20
percent. And you can see that not only has the number of tests grown significantly,
they've also been able to charge more. The revenue per test has gone from $600 to $1,500. So more
than doubling. And so that's the genomics. That's the data. You know, that's the testing segment.
But you do have this data segment, which I think could be even more interesting. So when you look
at it, it's about licensing libraries of de-identified. So that means you anonymize
the patient. You no longer have the exact detail who this person is, but you're taking their data,
their clinical, molecular and imaging data and providing a suite of analytical tools to pharmacy
and biotech companies. And they have 19 of the 20 largest public pharmacy companies licensing
their data. They have contracts with, you know, with these companies that say, hey, this data is
so valuable, they're willing to pay over 900 million dollars in the upcoming quarters. So
they have contracts, you know, for that to be delivered in the coming quarters. I suggest,
you know, this is a clear signal to me. This is a green flag for me. When I when I see this,
when I think about the potential moat that they're building and then I see the customers,
that's like a ding, ding, ding. That's a sign. This is valuable. And customers are saying,
you know, this this data set might help us refine creating better products that are more tailored
to very specific, you know, audiences to say, OK, this is, you know, with this genetic profile,
this is the the exact treatment that we need or this is, you know, this patient profile is more
likely to have a favorable or an adverse outcome. And this is also where AI comes in, because you
have just so much data. They say, look, you can answer questions in minutes, not months,
because you can have AI. And this is one of the strengths of AI, which is to be able to go through
just volumes of text and say, OK, here I can pull out all the references to this and say,
and may not even say the exact words. It's a context awareness to go through it all and then
say, OK, based on all these outcomes, here's where, you know, this patient population,
this is the this is the data that can be relevant for you as you're considering new products,
you know, new products to potentially come to market for the pharmaceutical and biotech
companies. So you can see why this, you know, it's starting to create a win win dynamic.
And not only do they have a lot of business committed for the next few years, 900 million
revenue, you know, to be delivered, but they're also seeing strong retention, 125 percent plus.
So that means their existing customers are paying 25 percent more. This data is valuable. I'm seeing
very clear signal. They're building something special in their data segment,
looking at their financials, growing at a nice clip around one hundred eighty million dollars
in the third quarter. So this is a pie. This is not a pie in the sky segment. This is not a business
that, you know, has has no real inherent value. This is not a meme coin.
There's a real business growing quickly. One hundred eighty million in revenue,
of which the vast majority is their genomics or their testing business. That's one hundred
sixteen million versus ninety six million. So growing at a reasonable clip, you know,
around 20 percent. But their data and services segment that grew very significantly from 40
million to sixty five million. You can also see the margin profile for genomics is around 50 percent
lower year over year, while data is around 77 percent. I look at this and I'm thinking to
myself, data is going to be really the driver of this business. That that would be my hunch,
you know, looking at this. And I would suspect the way you dominate over time is you say,
look, we're weak, perpetually lower the profile, the margin profile on the data,
on the the testing, the diagnostic testing business, because, you know, then you you know,
you don't have any sort of friction with, let's say, Congress or, you know, people saying,
oh, my goodness, these tests cost so much for for monitoring. No, you that profile just drops
more and more over time so people can use, you know, get these tests done more and more. But
then you're generating a lot more data that then can be used in this very profitable, highly,
you know, you can see much higher margin profile data segment. So I would expect the bulk of their
value will come from their data business over time. We'll see. That's that's my sort of hunch.
You can see it's still a negative EBITDA business, so negative cash flowing business,
so unprofitable, but growing quickly. They also announced an acquisition of Ambry Genetics,
which is one of the leading labs. They also have, you know, a testing platform with oncology,
neurology and cardiology. And the reason why this acquisition is so important for them is that also
it feed goes back into they're looking to grow their data moat. And so Ambry generates vast
amount of data across 400000 patients. And this also, you know, expands maybe, you know, reinforcing
their their diagnostic testing mode. It expands their access into new categories such as pediatrics,
rare disease, cardiology, reproductive health and immunology. So I look at this and, you know, it's
once again, I'm this is just an exploratory, you know, perspective on Tempest. But as excited as I
am about Tempest, it seems like they're making some clever acquisitions as well with Ambry.
And when I see the purchase price, you know, where they say, yeah, this is around 600 million dollars.
And initially I go, OK, that sounds like a lot of money. You know, more than half is in cash,
which I, you know, I'd rather see that you're using cash versus stock versus all stock. I don't
But looking at this, I mean, how many companies do you know are trading at two times revenue,
growing at 25 percent, are profitable on an EBITDA perspective, profitable on a free cash
flow perspective, you know, trading under two times. So I would say this is a very interesting
deal. There aren't a lot of companies like that. I you know, there there's a company that I'm
personally buying from my own personal portfolio. I've called out to my subscribers that, you know,
has similar profile, you know, around 30 percent growth and around two, three times sales.
But I'm very aware most companies do not, especially when you have significant gross
margins. And in this case, you have positive free cash flow. So this is or at least positive EBITDA.
So this is quite interesting. They are getting some financing from Ares and the deal is expected
to close in 2025. So I'd say this just adds to the complexity in terms of sizing up Tempest.
As we think about it, they're expecting around 30 percent growth, revenue growth for 2024.
When they report their full results, you can see that genomics growing around 30 percent and data
and services growing around 45 percent in the fourth quarter. And EBITDA is improving, though
still negative. However, with the acquisition of Ambry, they are expecting a 75 percent bump year
over year in revenue. So they'll be about one point two three billion in revenue for 2025.
And they do expect to be positive EBITDA, which is quite interesting because, you know, once you
get to the positive EBITDA phase, you know, getting closer to that positive free cash flow
phase, you know, you're talking about you're controlling your own destiny. You don't have
to rely on the capital markets as much. And that significantly de-risks the thesis. So this is
another example of, OK, there's there's real stake here. This isn't just sizzle that I like to see,
you know, thinking about. OK, so what about their valuation as we think about TEM or Tempest's
valuation? The stock, first of all, as always, is not financial advice. Also recently,
Harish, a premium member of the Unrivaled investing community, shared the following.
This is a direct quote. The profits I made from just one year from just one of your letters has
already covered the premium subscription for several years. This follows Matthew,
another premium member, saying Netflix, Spotify and Unrivaled are the only subscriptions I'll
never cancel. Seriously, this is an incredible value. If you're looking for compelling ideas,
come check out Unrivaled investing. When I think about my checklist, this checklist
really gets rid of 90 percent plus of the company's line management, compelling valuation,
obvious growth potential, no blow up risks and win-win. When I think about what we've covered
so far with Tempest, I think win-win is fairly obvious. If you're able to catch cancer early,
you know, fifteen hundred bucks is potentially a game changer, especially for the medical system.
You know, from an insurance perspective, the insurance company would say, wait a second,
this is great, as opposed to, let's say, having to spend hundreds of thousands of dollars on a
much more complex treatment. So I see win-win. I think for the scope of this video, you know,
there's just more work to be done in terms of sizing up the blow up risks in terms of
could there be some sort of competitor that disrupts one of their tests or, you know,
is there some sort of concentration? So that is something that needs further work, further
analysis. The obvious growth potential, you know, look, they're talking about 75 percent growth
next year, talking about how AI, this data set is, you know, clearly, you know, very valuable.
So I and I see diagnostic testing as just a clear win for, you know, how society goes,
you know, going forward. And then, you know, lastly, you know, you have compelling valuation,
which we'll talk about in just a second, and then aligned management. So we're covering the
majority of it. And for the most part, you know, this is this is doing fairly well. You know,
this is this is, I'd say, getting a pass or at least worth further study. So let's talk about
compelling valuation. Let's talk about aligned management, line management. That's also fairly
easy to see. Yes. The founder, CEO and chair, Eric Lefskovsky, you know, he holds around like
some honestly kind of sounds like Mike Wazowski. He holds around 40 million shares. He was selling
stock in December. But look, 40 million out of, let's say, around 170 million shares. That's a
huge interest. And he's look, he's the founder. So this this does get to the alignment that I want
to see when you have a founder is their baby. They want to build it. There's a pride of ownership
when you're a founder, you're a mercenary, you know, the mercenary versus missionary, you're
more likely to be a missionary to build something and to, you know, stay up late getting it done
versus the hired gun. So I love to see founder driven, you know, huge skin in the game. This is
what I like to see, even even if we was selling stock at, you know, lower prices in December,
you know, still broadly a huge share ownership. When I think about the valuation, this is a
hypothetical framework. Of course, stock price can go way higher, way lower, around seven and
a half billion dollar valuation at forty five dollars a share. You know, I'm thinking about
what's the revenue look like over the next five years? Because keep in mind, you have this
acquisition, that's a 75 percent jump. And then it's like, OK, are they growing at 15 percent
in the years ahead or 20 percent? So overall, that probably gets you to around two, two point
five, two point six billion in revenue potentially. And what's the margin profile for this? The data
segment alone has closer to 80 percent gross margin. But I do suspect the diagnostics could
be going lower over time. So this is a bit of uncertainty. What does their margin profile look
like? I suspect their debt is going to be higher than what I'm penciling out here in terms of their
interest expense because of that Aries financing. I also think, you know, my shares outstanding will
probably need a tweak because of this deal. So this is this is a very quick sort of back of
the envelope thinking about, you know, how does it look right now? But overall, you know, thinking
about, you know, just just based on very rough, I could see I could understand why investors would
say, oh, you know, there is still even after this jump, this you know, this this this BIP,
this jump, because, you know, this announcement that, you know, Representative Pelosi was buying
call options in the money, call options, a levered bet on Tempest caused the stock to jump 30, 40
percent. I suspect there still is potentially hundreds of percent upside over time. It just
really depends on how comfortable are you with saying that this business should be worth 30 to 35
times or that they will deliver around 30 percent growth for the next few years. So, you know, yes,
the the Ambry acquisition does sort of de-risk the growth rate in the immediate term. But I I look at
this and I say this this is definitely going to be one that I'm going to continue to monitor for
myself, for my subscribers at Unrivaled Investing, just because this is something, you know, I am
looking for those types of A.I. first companies that, you know, can benefit and can revolutionize,
you know, and do things that wasn't possible before. And I think Tempest does have that
potential based on taking all this data, analyzing it and providing valuable insights and seeing 19
of the 20 largest pharma companies saying, yeah, we want to pay for that. Not only do we want to
pay for that, but we're paying more each year, the one hundred twenty five percent net retention,
25 percent more from the existing cohort. So I look at that. Very interesting. I want to see how
things shake up a little bit. I probably need to refine the valuation framework, you know, looking
at adding the share count from their acquisition. And, you know, what do I think the actual growth
rate could be and look at their new products? There's a lot of exciting stuff here, though.
So this is, in my opinion, worth further study. There aren't, you know, most regular regular
viewers know. Oftentimes I'm like, well, you know, this isn't for me. I'm calling out how
this sort of goes through that checklist. This is, you know, you got the alignment, you got the,
you know, I'd say in very intriguing valuation, of course, if they don't execute, if the margins
don't end up anywhere near, you know, what I'm penciling out in the stock price could get,
you know, then then wouldn't surprise me if the stock falls significantly.
So it is worthwhile to understand these dynamics. But from what I'm looking at,
my initial checklist, I'm saying, OK, this is quite interesting. So if this video has been
helpful for you, I do appreciate you hitting that thumbs up, hit that subscribe button. Thanks so
much for watching Unrivaled Investing. And by the way, stay away from those meme coins. I don't
think they'll do you any good. Thanks for watching.
